The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
3 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $2,033,074 in first-year total cost, median $674,482.
Most frequent study sections
- Clinical Oncology Study Section[CONC]3
Most frequent institutions
- CHILDREN'S HOSPITAL OF LOS ANGELES1
- UNIVERSITY OF SOUTHERN CALIFORNIA1
- UNIVERSITY OF TX MD ANDERSON CAN CTR1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2015 | Tumor Heterogeneity and Acquired Resistance to EGFR Inhibition1R01CA184843-01A1 | HAMILTON, STANLEY R.KOPETZ, SCOTT | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $653,792 | CONC |
| 2014 | Molecular Diagnostics for Risk Stratification and Monitoring of Neuroblastoma1R01CA182633-01 | ASGHARZADEH, SHAHABSEEGER, ROBERT CHARLES | CHILDREN'S HOSPITAL OF LOS ANGELES, CA | $704,800 | CONC |
| 2014 | Biomarkers of Hormone Therapy Response in a Multicenter Prostate Cancer Trial1R01CA172436-01A1 | GOLDKORN, AMIRINGLES, SUE ANNPINSKI, JACEK | UNIVERSITY OF SOUTHERN CALIFORNIA, CA | $674,482 | CONC |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.